Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded Generate Biomedicines to “Sell” from “Hold,” diverging from the broader analyst consensus of “Moderate Buy,” based on six Buy ratings and one Hold rating.
• Analysts have raised their price targets, with Morgan Stanley at $22 and HC Wainwright at $25; the consensus target is $25.40 versus the stock’s Friday open of $14.35.
• Generate Biomedicines reported a quarterly loss of $0.52 per share, missing estimates by $0.04, while revenue totaled $6.31 million. Bank of New York Mellon also acquired a new stake valued at approximately $967,000.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other research firms have also commented on GENB. Morgan Stanley boosted their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. HC Wainwright lifted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $25.40.

Generate Biomedicines Stock Up 3.3%

Generate Biomedicines stock opened at $14.35 on Friday. The firm has a market capitalization of $1.84 billion and a price-to-earnings ratio of -13.41. The business's fifty day moving average is $14.45. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $18.18.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. On average, sell-side analysts forecast that Generate Biomedicines will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Generate Biomedicines stock. Bank of New York Mellon Corp acquired a new position in shares of Generate Biomedicines Inc (NASDAQ:GENB - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,326 shares of the company's stock, valued at approximately $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source